ABL1 and acute lymphoblastic leukemia: A NUP214::ABL1 (23) chimeric transcript usually corresponds to a T-lineage ALL phenotype (23, 24), and patients with this fusion gene can be effectively treated with tyrosine kinase inhibitors (TKI) (25, 26).